These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25270681)

  • 1. Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients.
    Lundqvist C; Beiske AG; Reiertsen O; Kristiansen IS
    J Neurol; 2014 Dec; 261(12):2438-45. PubMed ID: 25270681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden: an exploratory study.
    Kristiansen IS; Bingefors K; Nyholm D; Isacson D
    Appl Health Econ Health Policy; 2009; 7(3):167-80. PubMed ID: 19799471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
    J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
    Noyes K; Dick AW; Holloway RG;
    Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.
    Palmer CS; Nuijten MJ; Schmier JK; Subedi P; Snyder EH
    Pharmacoeconomics; 2002; 20(9):617-28. PubMed ID: 12141889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
    Groenendaal H; Tarrants ML; Armand C
    Clin Drug Investig; 2010; 30(11):789-98. PubMed ID: 20818839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.
    Lowin J; Bergman A; Chaudhuri KR; Findley LJ; Roeder C; Schifflers M; Wood E; Morris S
    J Med Econ; 2011; 14(5):584-93. PubMed ID: 21728911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protocol of a randomized open label multicentre trial comparing continuous intrajejunal levodopa infusion with deep brain stimulation in Parkinson's disease - the INfusion VErsus STimulation (INVEST) study.
    van Poppelen D; Sisodia V; de Haan RJ; Dijkgraaf MGW; Schuurman PR; Geurtsen GJ; Berk AEM; de Bie RMA; Dijk JM
    BMC Neurol; 2020 Jan; 20(1):40. PubMed ID: 32005175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
    Noyes K; Dick AW; Holloway RG;
    Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
    Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
    Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life.
    Puente V; De Fabregues O; Oliveras C; Ribera G; Pont-Sunyer C; Vivanco R; Cucurella G; Giralt E; Delgado T; Garcia C; Seoane A; Campo R
    Parkinsonism Relat Disord; 2010 Mar; 16(3):218-21. PubMed ID: 19762271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
    Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
    J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacoeconomic study of the treatment of advanced Parkinson's disease].
    Vivancos-Matellano F; Garcia-Ruiz AJ; Garcia-Agua Soler N
    Rev Neurol; 2016 Dec; 63(12):529-536. PubMed ID: 27897303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of pramipexole in Parkinson's disease in the US.
    Hoerger TJ; Bala MV; Rowland C; Greer M; Chrischilles EA; Holloway RG
    Pharmacoeconomics; 1998 Nov; 14(5):541-57. PubMed ID: 10344917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
    Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
    J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review.
    Smilowska K; van Wamelen DJ; Pietrzykowski T; Calvano A; Rodriguez-Blazquez C; Martinez-Martin P; Odin P; Chaudhuri KR
    J Parkinsons Dis; 2021; 11(2):475-489. PubMed ID: 33386813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study.
    Zibetti M; Merola A; Ricchi V; Marchisio A; Artusi CA; Rizzi L; Montanaro E; Reggio D; De Angelis C; Rizzone M; Lopiano L
    J Neurol; 2013 Jan; 260(1):105-14. PubMed ID: 22772358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.